409 related articles for article (PubMed ID: 30779980)
1. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
[TBL] [Abstract][Full Text] [Related]
2. Anisamide-targeted gold nanoparticles for siRNA delivery in prostate cancer - synthesis, physicochemical characterisation and in vitro evaluation.
Fitzgerald KA; Rahme K; Guo J; Holmes JD; O'Driscoll CM
J Mater Chem B; 2016 Apr; 4(13):2242-2252. PubMed ID: 32263220
[TBL] [Abstract][Full Text] [Related]
3. Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells.
Guo J; O'Driscoll CM; Holmes JD; Rahme K
Int J Pharm; 2016 Jul; 509(1-2):16-27. PubMed ID: 27188645
[TBL] [Abstract][Full Text] [Related]
4. Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumor-bearing mice.
Wang L; Pei J; Cong Z; Zou Y; Sun T; Davitt F; Garcia-Gil A; Holmes JD; O'Driscoll CM; Rahme K; Guo J
Int J Nanomedicine; 2019; 14():1817-1833. PubMed ID: 30880982
[TBL] [Abstract][Full Text] [Related]
5. Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells.
Rahme K; Guo J; Holmes JD
Methods Mol Biol; 2019; 1974():291-301. PubMed ID: 31099011
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery.
Rahme K; Guo J; Holmes JD; O'Driscoll CM
Colloids Surf B Biointerfaces; 2015 Nov; 135():604-612. PubMed ID: 26322474
[TBL] [Abstract][Full Text] [Related]
7. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice.
Guo J; Ogier JR; Desgranges S; Darcy R; O'Driscoll C
Biomaterials; 2012 Nov; 33(31):7775-84. PubMed ID: 22828585
[TBL] [Abstract][Full Text] [Related]
8. A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor.
Fitzgerald KA; Malhotra M; Gooding M; Sallas F; Evans JC; Darcy R; O'Driscoll CM
Int J Pharm; 2016 Feb; 499(1-2):131-145. PubMed ID: 26721726
[TBL] [Abstract][Full Text] [Related]
9. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-L-lysine nanocarrier to suppress prostate cancer growth in mice.
Guo J; Cheng WP; Gu J; Ding C; Qu X; Yang Z; O'Driscoll C
Eur J Pharm Sci; 2012 Apr; 45(5):521-32. PubMed ID: 22186295
[TBL] [Abstract][Full Text] [Related]
11. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
12. Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells.
Mitra M; Kandalam M; Rangasamy J; Shankar B; Maheswari UK; Swaminathan S; Krishnakumar S
Mol Vis; 2013; 19():1029-38. PubMed ID: 23687439
[TBL] [Abstract][Full Text] [Related]
13. Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers.
Mendes LP; Sarisozen C; Luther E; Pan J; Torchilin VP
Drug Deliv; 2019 Dec; 26(1):443-458. PubMed ID: 30929529
[TBL] [Abstract][Full Text] [Related]
14. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
15. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
16. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery.
Song WJ; Du JZ; Sun TM; Zhang PZ; Wang J
Small; 2010 Jan; 6(2):239-46. PubMed ID: 19924738
[TBL] [Abstract][Full Text] [Related]
17. PEGylated polyethylenimine-entrapped gold nanoparticles modified with folic acid for targeted tumor CT imaging.
Zhou B; Yang J; Peng C; Zhu J; Tang Y; Zhu X; Shen M; Zhang G; Shi X
Colloids Surf B Biointerfaces; 2016 Apr; 140():489-496. PubMed ID: 26812636
[TBL] [Abstract][Full Text] [Related]
18. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
Liu L; Zheng M; Librizzi D; Renette T; Merkel OM; Kissel T
Mol Pharm; 2016 Jan; 13(1):134-43. PubMed ID: 26641134
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
[TBL] [Abstract][Full Text] [Related]
20. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy.
Lu ZX; Liu LT; Qi XR
Int J Nanomedicine; 2011; 6():1661-73. PubMed ID: 21904456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
